Rethinking the secondary prevention of superficial bladder cancer: Is there a role for retinoids?

BJU International

Volumn 85, Issue 9, 2000, Pages 1023-1026

  Nutting, C ^a,b   Huddart, R A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE; FENRETINIDE; RETINOID; VITAMIN;

BLADDER CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRY SKIN; DYSPEPSIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TUMOR RECURRENCE;

HUMANS; NEOPLASM RECURRENCE, LOCAL; RETINOIDS; URINARY BLADDER NEOPLASMS;

EID: 0034038983     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00655.x     Document Type: Short Survey

References (30)

1. Black RJ, Bray F, Ferlay J et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-107
2. Bono AV. Superficial bladder cancer: state of the art. Cancer Chemother Pharmacol 1994; 35: S101-9
3. Cookson MS, Herr HW, Zhang Z et al. The treated natural history of high risk bladder cancer: 15-year outcome. J Urol 1997; 158: 62-7
4. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organisation for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. J Urol 1996; 156: 1934-41
5. Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. New Eng J Med 1992; 326: 737-406
6. Kurth KH, Schroeder FH, Tunn U et al. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of an EORTC randomised trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. J Urol 1984; 132: 258
7. McBurney MW, Costa S, Pratt MAC. Retinoids and cancer: a basis for differentiation therapy. Cancer Invest 1993; 11: 590-8
8. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-64
9. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventative and therapeutic anticancer agents. Cancer Treatment Reports 1987; 71: 493-515
10. Lippman SM, Hong WK. Retinoid chemoprevention of upper acrodigestive tract carcinogenesis. In DeVita VT, Hellman S, Rosenburg SA, eds, Important Advances in Oncology 1992, Chapter 6. Philadelphia: Lippincott, 1992: 93-109
11. Muindi JRF, Young CW, Warrell RP. Clinical pharmacology of all-trans-retinoic acid. Leukaemia 1994; 8: 1807-12
12. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD. The safety of etretinate as long term therapy for psoriasis: Results of the etretinate follow-up study. J Am Acad Dermatol 1995; 33: 44-52
13. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-S12
14. Masters JRW, Hepburn PJ, Walker L et al. Tissue culture model of transitional cell carcinoma: characterisation of twenty two human urothelial cell lines. Cancer Res 1986; 46: 3630-6
15. Nutting C, Chowaniec J. Evaluation of the actions and interactions of epidermal growth factor and retinoic acid on transformed urothelial cells in culture: Implications for the use of retinoid therapy in the treatment of bladder cancer patients. Clin Oncol 1992; 4: 51-5
16. Wolbach SB, Howe PR. Tissue changes following deprivation of fat soluble vitamin A. J Exp Med 1925; 42: 753-77
17. Sporn MB, Squire RA, Brown CC, Smith JM, Wenk ML, Springer S. 13-cis-Retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 1977; 195: 487-9
18. Moon RC, McCormick DL, Becci PJ et al. Influence of 15 retinoic acid amides on urinary carcinogenesis in the mouse. Carcinogenesis 1982; 12: 1469-72
19. Mathews-Roth MM, Lausen N, Drouin A, Krinsky NI. Effects of carotenoid administration on bladder cancer prevention. Oncology 1991; 48: 177-9
20. Moon RC, Detrisac CJ, Thomas CF, Kelloff GJ. Chemoprevention of experimental bladder cancer. J Cell Biochem 1992; 161: 134-8
21. Pemrick SM, Lucas DA, Grippo JF. The retinoid receptors. Leukaemia 1994; 8: S1-10
22. Mettlin C, Graham S. Dietary risk factors in human bladder cancer. Am J Epidemiol 1979; 110: 255-61
23. Mayne ST, Lippman SM. Retinoids and carotenoids. In DeVita VT, Hellman S, Rosenburg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997: 585-99
24. Peto R, Doll R, Buckley JD et al. Can dietary B-carotene materially reduce human cancer rates? Nature 1981; 290: 201-8
25. Alfthan O, Tarkkanen J, Grohn P, Heinonem E, Pyrhonen S, Saila K. Tigason (etretinate) in prevention of recurrences of superficial bladder tumours: a double blind clinical trial. Eur Urol 1983; 9: 6-9
26. Studer UE, Biedermann C, Chollet D et al. Prevention of recurrent superficial bladder tumours by oral etretinate: Preliminary results of a randomised, double blind multicenter trial in Switzerland. J Urol 1984; 131: 47-9
27. Studer UE, Jenzer S, Biedermann C et al. Adjuvant treatment with a Vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumours: Final analysis of a prospective, randomized multicentre trial in Switzerland. Eur Urol 1995; 28: 284-90
28. Decensi A, Bruno S, Costantini M et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end-point. J Nat Cancer Inst 1994; 86: 138-9
29. Sabichi AL, Lerner SP, Grossman HB, Lippman SM. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol 1998; 10: 479-84
30. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double blind clinical trial. J Urol 1994; 151: 21-6